title: Efficacy of rituximab in refractory antisynthetase syndrome.
abstract: We report the successful use of repeated administration of rituximab in a patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. A literature review revealed that previous experience with rituximab in this condition has been sparse. The rationale for the use of B-cell depleting therapies in antisynthetase syndrome has been explored in light of the current understanding of the pathogenesis of this condition.
authors.affiliation: Rheumatology Department, Royal Adelaide Hospital, South Australia, Australia. vidya.limaye@health.sa.gov.au
authors.forename: V
authors.initials: V
authors.lastname: Limaye
authors.forename: P
authors.initials: P
authors.lastname: Hissaria
authors.forename: C-L
authors.initials: CL
authors.lastname: Liew
authors.forename: B
authors.initials: B
authors.lastname: Koszyka
mesh_terms: D000328:Adult; D000604:Amino Acyl-tRNA Synthetases / Q000276:immunology*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001323:Autoantibodies / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D003882:Dermatomyositis / Q000188:drug therapy* / Q000276:immunology; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000276:immunology; D010257:Paraneoplastic Syndromes / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D012074:Remission Induction; D000069283:Rituximab; D013577:Syndrome; D002583:Uterine Cervical Neoplasms / Q000150:complications; D002578:Uterine Cervical Dysplasia / Q000150:complications
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D001324:Autoantigens; D015415:Biomarkers; D018395:CA-19-9 Antigen; D007166:Immunosuppressive Agents; D000069283:Rituximab; D000604:Amino Acyl-tRNA Synthetases